Request a Quote |
ADME PK

Reactive metabolite assessment (stable label glutathione trapping)

  • Reactive metabolite formation is thought to be one of the primary causes of idiosyncratic adverse drug reactions, often associated with drug-induced skin, liver and hematopoietic toxicities.
  • Reactive metabolites, formed via drug metabolism in the body, are electrophilic species which can bind covalently to macromolecules such as proteins and DNA, affecting their function and potentially leading to toxicity.
  • To minimize the risk of later stage failure - which is of considerable financial burden to the Pharmaceutical Industry - screening for reactive metabolite formation at an early stage in lead optimization is now common practice1.
  • Chemical trapping agents, such as reduced glutathione (GSH), can form stable adducts with many reactive species. Trapping agents, incubated with liver microsomes, are now routinely used in the identification of reactive metabolites.
  • By using high resolution accurate mass spectrometry, it improves detection of the conjugates and allows superior structural characterisation. The process utilises MSE data acquisition, mass detect filtering and post acquisition data mining.
  • Cyprotex now offers the reactive metabolite screen with the addition of stable label glutathione, which, when incubated in a 1:1 ratio with unlabelled glutathione, produces an easily recognisable isotopic doublet with a difference of 3 amu. This additional diagnostic tool increases the robustness of identified conjugations.
Screening and structural characterization of reactive metabolites, as one of the major efforts to reduce attrition in drug development, has increasingly become an integral part of the ADMET-guided lead optimization process in drug discovery.

2 Yan Z, Maher N, Torres R, Caldwell GW and Huebert N (2005) Rapid Commun Mass Spectrom 19; 3322-3330

Protocol

Reactive metabolite formation by stable label glutathione trapping

Assay Design Test article incubated with human liver microsomes and glutathione in the presence and absence of NADPH
Test Article Concentration 50 µM
Microsomal Concentration 1 mg/mL
Glutathione Concentration 1 mM (1:1 ratio of unlabelled to stable label)
Quality Controls Minus NADPH (negative control)
Ticlopidine (positive control)
Test Article Requirements 100 µL of 10 mM DMSO solution or equivalent amount of solid compound
Analysis Method High resolution accurate mass Q-TOF
Data Delivery Summary report including:
  • LC-MS chromatograms of the parent and reactive metabolites, along with spectra with and without fragmentation
  • Table including mass, name of proposed metabolite and formula, m/z found, mass error, retention time, absolute area, and area percentage
Structural elucidation (optional)

Comprehensive report (optional)

Data

Data for reactive metabolite formation (stable label glutathione trapping)

 
Figure 1
Representative XIC chromatogram of ticlopidine following incubation with human liver microsomes and stable and unlabelled glutathione in the absence and presence of NADPH.
 
Figure 2
High energy MSE spectrum for ticlopidine + hydration + GSH following incubation with human liver microsomes, stable label and unlabelled glutathione, and NADPH.
NameFormulam/z FoundMass Error (ppm)IdentifierRT (min)Neutral LossStable Label Observed
Parent C14H14ClNS 264.0616 1.0 Parent 3.26 - -
GSH + reduction C24H31ClN4O6S2 571.1449 -0.4 M1 2.69 305, 307 Yes
GSH + hydration C24H31ClN4O7S2 587.1397 -0.6 M2 2.47 75, 129, 307 Yes
GSH + hydration C24H31ClN4O7S2 587.1393 -1.3 M3 2.53 307 Yes

Table 1

Table illustrating representative data for ticlopidine following incubation with human liver microsomes and stable label and unlabelled glutathione in the presence of NADPH.

References

1 Evans DC et al. (2004) Drug−protein adducts:  An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 17(1); 3-16

2 Yan Z et al. (2005) Rapid detection and characterization of minor reactive metabolites using stable-isotope trapping in combination with tandem mass spectrometry. Rapid Commun Mass Spectrom 19(22); 3322-3330

Learn More

Learn more about toxicology in our popular Mechanisms of Drug-Induced Toxicity guide

Order your copy

Tox guide
Get a Quote
Product sheet ADME Guide DDI Guide TOX Guide

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): +1-888-297-7683
Europe: +44 (0)1625 5051000

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

By clicking on ‘Send’ I agree that my data is being transferred and used by Cyprotex and the affiliated Evotec Group. The Evotec Group currently consists of the following companies. For further details please see our privacy policy.

If you would like to be kept informed of our latest services, new research, events and other news please tick the box below:

Close